Cleveland Clinic

Vinmec's Innovations Spotlighted at Global CSR & ESG Summit 2024

Retrieved on: 
星期三, 五月 8, 2024
Education, Spectrum, Cleveland Clinic, Workplace, Vaccine, Culture, Patient safety, Accreditation, Medicine, JCI, Caesars Entertainment, Knowledge, AstraZeneca, Technology transfer, Haematopoietic system, CSR, Professional, Ageing, Molina Healthcare, COE, Hospital, GE HealthCare, Heart, PDSA, Research, Accountability, 3D, OMICS Publishing Group, CARE, Family, Immunology, Health, Ethics, Center of excellence, Organization, Platinum, Joint Commission, Empowerment, Interview, American College, Creativity, Leukemia, Environment, Patient, ESG, Cerebral palsy, COVID-19, Growth, Nursing

HANOI, Vietnam, May 9, 2024 - (ACN Newswire) - The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam.

Key Points: 
  • HANOI, Vietnam, May 9, 2024 - (ACN Newswire) - The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam.
  • The event showcased tremarkable strides in corporate social responsibility (CSR) and environmental, social, and governance (ESG) initiatives, and featured some of the most outstanding achievements by enterprises and organizations in this regard.
  • ACN: Can you share with us the vision and mission of Vinmec, particularly its dedication to academic healthcare for people at local and global scales?
  • Our emphasis on cutting-edgeinnovative applications like 3D printing and robotic surgery ensures clinical excellence and value-based solutions for our patients.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in May

Retrieved on: 
星期五, 五月 10, 2024
Assistant professor, AFL, Research, Cleveland Clinic, Serum, Coeliac disease, Psychiatry, Multiple sclerosis, Communication, DDW, SIRT6, Annual general meeting, CMSC, Biotechnology, Pharmaceutical industry

NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

Key Points: 
  • NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
    May 12-14 and 21-22: Bio€quity Europe 2024.
  • Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in San Sebastián, Spain and virtually.
  • To schedule a meeting, please use the Bio€quity conference portal or contact Jessica Breu at: [email protected] .
  • Presentation Title: Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial

EQS-News: neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on: 
星期五, 五月 10, 2024
Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Key Points: 
  • neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector
    The issuer is solely responsible for the content of this announcement.
  • neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector
    Tariq previously held leadership roles at Dubai Healthcare City, Mubadala Healthcare's Cleveland Clinic Abu Dhabi, and Proximie
    Dubai, UAE and Munich, Germany, 7.
  • May 2024 - neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.
  • Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
星期三, 五月 8, 2024
Science, FDA, AMD, Investment, DOI, Safety, OIS, Stuart, Florida, Food, Research, Cleveland Clinic, Growth, FACS, KOL, Therapy, Thomas Jefferson University, Eye, Wills Eye Hospital, Marketing, DME, Clinical trial, Associate, Diabetic retinopathy, ARVO, Plasma, Uveitis, Pharmaceutical industry

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate developments.

Key Points: 
  • The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data in the third quarter of 2024.
  • EyePoint plans to host an R&D Day on June 26, 2024 in New York City.
  • Net product revenue for the first quarter was $0.7 million, compared to net product revenues for the first quarter ended March 31, 2023 of $7.4 million.
  • Operating expenses for the first quarter ended March 31, 2024 totaled $45.0 million versus $29.2 million in the prior year period.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
星期三, 五月 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, Multimedia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/texas-cardiac-arrhythmia-instit...
    SOURCE Texas Cardiac Arrhythmia Institute at St. David’s Medical Center

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
星期三, 五月 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • Physicians received a maximum of 14.5 American Medical Association (AMA) Physician's Recognition Award (PRA) Category 1 Credit™ hours at the conference.

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines

Retrieved on: 
星期三, 五月 8, 2024
JDA, Cancer, Prostate, Protein, Inflammation, Cleveland Clinic, Breast, Sidoti, Doctor of Philosophy, National Cancer Institute, Conference, Vaccine, Research, Incidence, Neoplasm, Lung, Malignancy, TNBC, Ovarian cancer, Breast cancer

SAN JOSE, Calif., May 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types. Cleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer (TNBC), the most aggressive and lethal form of breast cancer, and an ovarian cancer vaccine is in pre-clinical development in collaboration with the National Cancer Institute.

Key Points: 
  • Cleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer (TNBC), the most aggressive and lethal form of breast cancer, and an ovarian cancer vaccine is in pre-clinical development in collaboration with the National Cancer Institute.
  • The vaccines focus on a novel scientific mechanism never used before in a cancer vaccine.
  • The vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences.
  • Anixa Chairman and CEO Dr. Amit Kumar stated, "Cleveland Clinic is a valued partner to Anixa in the development of both breast and ovarian cancer vaccines.

Bridge to Life Announces Late-Breaker, Oral and Poster Presentations on Bridge to HOPE trial with VitaSmart at 2024 American Transplant Congress (ATC) in Philadelphia, PA, June 1-5, 2024

Retrieved on: 
星期三, 五月 8, 2024
University, Safety, Clinical trial, The, HOPE, Hope, Perfusion, Abstract, Cleveland Clinic, ATC, University of Iowa, Dietary supplement

CHICAGO, May 8, 2024 /PRNewswire/ -- Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced acceptance of four abstracts based on data from its U.S. pivotal clinical trial on HOPE using the VitaSmart Liver Machine, including a late-breaker, for presentation at the 2024 annual meeting of the American Transplant Congress (ATC). The conference is scheduled to take place in Philadelphia, PA from June 1-5, 2024. VitaSmart is not currently approved for use in the US.

Key Points: 
  • The conference is scheduled to take place in Philadelphia, PA from June 1-5, 2024.
  • VitaSmart is not currently approved for use in the US.
  • Three presentations will be oral, including a late-breaker, and one will be a poster presentation.
  • June 4 (Poster Session): Economic Assessment Of Hypothermic Oxygenated Machine Perfusion In Liver Transplantation: Interim Analysis, D. Axelrod, University of Iowa, Iowa City, IA et al.

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on: 
星期二, 五月 7, 2024
Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

DUBAI, UAE, May 7, 2024 /PRNewswire/ -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.

Key Points: 
  • Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership roles.
  • Throughout his career, Tariq has worked in various private and publicly listed multinationals, semi-government organizations, and start-up companies across the UK, Europe, and the Middle East.
  • Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.
  • "We warmly welcome Tariq to the neurocare team," said Thomas Mechtersheimer, CEO of neurocare Group AG.

neurocare group AG appoints Tariq El-Titi as Senior Vice President MENA, strengthening commitment to Middle East health sector

Retrieved on: 
星期二, 五月 7, 2024
Janus, Investment, Dubai Healthcare City, Health, Cleveland Clinic, AG, Growth, Senior, GCC, Mental health, Cleveland Clinic Abu Dhabi, Management

DUBAI, UAE, May 7, 2024 /PRNewswire/ -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, today announced the appointment of Tariq El-Titi as Senior Vice President for the Middle East and North-Africa (MENA) region.

Key Points: 
  • Tariq is a seasoned healthcare specialist, bringing with him a wealth of experience in healthcare start-up ventures and strategic C-level leadership roles.
  • Throughout his career, Tariq has worked in various private and publicly listed multinationals, semi-government organizations, and start-up companies across the UK, Europe, and the Middle East.
  • Focused on bringing disruptive new health technologies to the Middle East, Tariq founded Janus Ventures in 2018, underscoring his commitment to driving innovation in the healthcare sector.
  • "We warmly welcome Tariq to the neurocare team," said Thomas Mechtersheimer, CEO of neurocare Group AG.